Z-1436-2021 Class II Terminated
FDA device recall Z-1436-2021 was initiated by Stryker Leibinger GmbH & Co. KG on Apr 1, 2021 and is designated Class II. Reason for recall: Inability for the user to inject the paste from the syringe into the target location. The recall status is terminated (terminated Dec 19, 2022). Affected quantity: 321 units.
Recall details
- Product Type
- Devices
- Report Date
- Apr 28, 2021
- Initiation Date
- Apr 1, 2021
- Termination Date
- Dec 19, 2022
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 321 units
Product description
DirectInject consists of a sterile dual paste system which is calcium phosphate based. Upon injection through the Mixer-Cannula, the two pastes form a cement paste which is moldable. The injected cement paste will harden under normal body conditions to form hydroxyapatite.
Reason for recall
Inability for the user to inject the paste from the syringe into the target location.
Distribution pattern
Worldwide distribution - US Nationwide distribution and the countries of Germany, Italy, France, Australia, Japan.
Code information
Lot: DI20311,DI20307 Product Code (UDI): 07613327123265
Source
- Dataset
- openFDA device recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for Z-1436-2021
- openFDA file date
- Nov 10, 2026
- Loaded by RegDataLab
- Nov 11, 2026